In Reply As stated in the panel’s report,1 the relative absence of resistance-conferring mutations for InSTI drugs supports the recommendation to not test routinely for InSTI resistance before start of HIV treatment. A summary of existing data regarding the relative lack of transmission of InSTI resistance–conferring mutations was published this year.2
Saag MS, Günthard HF, Smith DM. Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment—Reply. JAMA. 2018;320(20):2154. doi:10.1001/jama.2018.15946
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: